Merck and Roche Targets Sun and Caraco Over Ganirelix
Merck, MSD, Organon and Roche (”Plaintiffs”) have launched a complaint against Sun Pharmaceutical Industries, Inc. and Caraco Pharmaceutical Laboratories ( “Defendants”) in the U.S District Court of New Jersey on Aug 27, 2012 for patent infringement (case no. 3:12-cv-05374).
Organon is the holder of the approved New Drug Application for Ganirelix Acetate Injection. Ganirelex is approved to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
U.S Patent No. |
Current Assignee source: Maxval’s Assignment DB* |
Date of Issue/Projected Expiration Date |
Title
|
Syntex (as per the patent facepage); Syntex was acquired by Roche |
June 16, 1998
|
“Nonapeptide and Decapeptide Analogs of LHRH Useful as LHRH Antagonists,” |
|
MSD |
Nov. 25, 2003
|
“Gonadotropin Releasing Hormone Antagonist,” |
According to the complaint, defendants submitted Abbreviated New Drug Application (No. 20-4246) to obtain approval from FDA to engage in the commercial manufacture and sale of Ganirelix Acetate for Injection* (source: Maxval’s Patent Marker) that is covered by USPN 5767082 and USPN 6653286 . These patents have not been asserted before.
For more details, visit Maxval-IP and subscribe to our Litigation Alerts.
* Patent Assignment Alerts are automated email alerts sent to you when assignments relating to target applications/patents/entities of interest are recorded.
* Patent Marker provides an online environment for patentees and the public to mark products with patent numbers and to search for patent related details about products.
Comment
Support
Add your Twitter profile!
Events
© 2013 Created by Mikk Putk.
You need to be a member of Intellectual Property Insiders to add comments!
Join Intellectual Property Insiders